alexa
Reach Us +1-504-608-2390
DNA Abasic Lesion Is Cleaved By Antibiotic Drugs Aminoglycosides: A Promising Effect That Could Potentiate Antitumor Genotoxic Agents | 58480
ISSN: 2161-0495

Journal of Clinical Toxicology
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

DNA abasic lesion is cleaved by antibiotic drugs aminoglycosides: A promising effect that could potentiate antitumor genotoxic agents

6th Global Summit on Toxicology & Applied Pharmacology

Maralise Perigolo de Oliveira, Jean-Francois Constant, Marine Peuchmaur, Ivan Pitta and Jean-Luc Decout

University of Grenoble, France

Posters & Accepted Abstracts: J Clinic Toxicol

DOI: 10.4172/2161-0495.C1.019

Abstract
Abasic sites are probably the most common lesions in DNA. They result from the hydrolytic cleavage of glycosidic bonds that can occur spontaneously and during the repair processes of damaged nucleic bases produced by anticancer alkylating agents and radiotherapy. If not repaired, the abasic site can be mutagenic or lethal. Thus, compounds able to specifically bind and react to abasic sites have attracted much attention for therapeutic and diagnostic purposes. Here, we report on the efficient cleavage activity of natural aminoglycosides (AG) antibiotic drugs at abasic sites. Neomycin B appeared to be the most efficient compound (EC50=0.1μM). This cleavage activity could be related to the aminoglycoside toxicity but could also find medicinal applications through potentiation of cancer radiotherapy and chemotherapy with alkylating drugs.
Biography

Maralise Perígolo de Oliveira has completed her Master’s from University Grenoble Alpes and PhD from Pernambuco Federal University (Brazil) in 2014. Since 2015, she is involved in her Post-doctoral research in Medicinal Chemistry from Belo Horizonte (Brazil) through collaboration from Pernambuco Federal University and Federal University of Minas Gerais.

Email: [email protected]

Top